Serotonin antagonists and reuptake inhibitors treat depression by increasing synaptic serotonin
the verdict
SUPPORTED
the evidence backs this
confidence 86/100
Clinical and neuroimaging studies consistently demonstrate that serotonin reuptake inhibitors and related antidepressant medications achieve their therapeutic effects in part by binding to and blocking serotonin transporters, thereby increasing synaptic serotonin levels.
Evidence for · 4
Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder
2012 · cited by 45
Demonstrates that TCAs and SSRIs share a mechanism of action via serotonin transporter inhibition.
See more details
More for · 3
Serotonin Transporter Occupancy and the Functional Neuroanatomic Effects of Citalopram in Geriatric Depression
2011 · cited by 28
Shows that SSRI treatment results in significant serotonin transporter occupancy in human brain regions.
Molecular Imaging of the Serotonin Transporter Availability and Occupancy by Antidepressant Treatment in Late-Life Depression
2021 · cited by 14
Finds that antidepressant treatment leads to high serotonin transporter occupancy which correlates with clinical improvement.
Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.
2026 · cited by 4
Confirms that widely prescribed antidepressants like SSRIs and SNRIs were developed based on monoaminergic neurotransmission hypotheses.